Magnesium in Aneurysmal Subarachnoid Hemorrhage (MASH II) Phase III Clinical Trial MASH-II Study Group
Abstract
Rationale
Delayed cerebral ischemia (DCI) is an important cause of poor outcome after aneurysmal subarachnoid hemorrhage (SAH). Magnesium is a neuroprotective agent that acts as an NMDA-receptor antagonist and a calcium channel blocker. In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.
Aims
To determine whether magnesium improves clinical outcome in patients with aneurysmal SAH.
Design
The MASH-II study is a phase III randomized, clinical international multicenter trial. Magnesium sulfate 64 mmol/ day (equals 16 g/day) or placebo is started intravenously within 4 days after the SAH and is continued until 20 days after the hemorrhage. The primary outcome measure is poor outcome, defined as death or dependence (Rankin score > 3) after 3 months. We aim to include 1200 patients in 5 years. Study outcomes Primary outcome will be poor clinical outcome as measured by the modified Rankin scale at 3 months. Sponsor MASH-II is sponsored by the Netherlands Heart Foundation (grant number: 2005BO16). It is registered with IRCTN number: 68742385, EudraCT: 2006-003523-36.
Introduction
Subarachnoid hemorrhage (SAH) from a ruptured aneurysm is a subset of stroke. The young age (median 55 years) and poor outcome (50% of patients die; 30% of those who survive the initial weeks after the hemorrhage remain dependent) explain why in the population the loss of productive life years from SAH is as large as that from brain infarcts, the most common type of stroke (1).
Summary
The MASH-II study is a phase III randomized, clinical international multicenter trial to study the effect of magnesium sulfate after aneurysmal SAH. Magnesium is a neuroprotective agent that acts as a blocker of both the NMDA-glutamate receptor and voltage dependent calcium channels. Patients who are admitted within 4 days after aneurysmal SAH are asked to participate. Study medication (magnesium sulfate 64 mmol/ day or placebo) is given via continuous infusion until 20 days after the hemorrhage. Outcome is determined with the modified Rankin scale 3 months after the hemorrhage. Analysis will be according to the intention-to-treat principle. So far, in May 2007 over 425 patients have been included in five Dutch and one Chilean hospital. Based on the results of the phase II study sample size calculations indicate that 1200 patients are needed to give a statistically significant result (with α = 5% and a power of 80%). We aim to include these patients before 2010. New centers are still very welcome to join the study.
Get full access to this article
View all access and purchase options for this article.
References
1 Hop JW, Rinkel GJ, Algra A, van Gijn J: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997; 28:660–4.
2 Brilstra EH, Rinkel GJ, Algra A, van Gijn J: Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage. Neurology 2000; 55:1656–60.
3 Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M: Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 2000; 68:337–41.
4 McLean RM: Magnesium and its therapeutic uses: a review. Am J Med 1994; 96:63–76.
5 Altman D, Carolli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877–90.
6 Belfort MA, Anthony J, Saade GR, Allen JC Jr: A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003; 348:304–11.
7 van den Bergh WM, Dijkhuizen RM, Rinkel GJ: Potentials of magnesium treatment in subarachnoid haemorrhage. Magnes Res 2004; 17:301–13.
8 van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005; 36:1011–15.
9 Dorhout Mees S, Rinkel G, Feigin V, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev; 2007; CD000277.
10 van den Bergh WM, Albrecht KW, Berkelbach van der Sprenkel JW, Rinkel GJ: Magnesium therapy after aneurysmal subarachnoid haemorrhage a dose-finding study for long term treatment. Acta Neurochir (Wien) 2003; 145:195–9.
11 van Norden AG, van den Bergh WM, Rinkel GJ: Dose evaluation for long-term magnesium treatment in aneurysmal subarachnoid haemorrhage. J Clin Pharm Ther 2005; 30:439–42.
12 van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604–7.
13 Newcommon NJ, Green TL, Haley E, Cooke T, Hill MD: Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2003; 34:377–8.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: February 1, 2008
Issue published: February 2008
Keywords
PubMed: 18705917
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in International Journal of Stroke.
VIEW ALL JOURNAL METRICSArticle usage*
Total views and downloads: 149
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 19 view articles Opens in new tab
Crossref: 0
-
Targeted Temperature Management for Subarachnoid Hemorrhage: Excellent...
-
Postoperative analgesia in the surgical treatment of non-traumatic sub...
-
Therapeutics targeting the inflammasome after central nervous system i...
-
Preventive effect of continuous cisternal irrigation with magnesium su...
-
Del vasoespasmo a la lesión cerebral precoz: una nueva frontera en la ...
-
From vasospasm to early brain injury: New frontiers in subarachnoid ha...
-
Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomis...
-
New therapeutic approaches to subarachnoid hemorrhage
-
Magnesium in Ischemic Stroke and Subarachnoid Hemorrhage
-
Causes of neurological deficits following clipping of 200 consecutive ...
-
Resistant Vasospasm in Subarachnoid Hemorrhage Treated with Continuous...
-
Perioperative Management of Subarachnoid Hemorrhage
-
Critical Care of the Patient with Acute Stroke
-
Magnesium sulfate for aneurysmal subarachnoid hemorrhage: the end of t...
-
Is There a Future for Neuroprotective Agents in Cardiac Surgery?
-
A Review of Delayed Ischemic Neurologic Deficit Following Aneurysmal S...
-
Multidisciplinary management and emerging therapeutic strategies in an...
-
Prophylactic intravenous magnesium sulfate for treatment of aneurysmal...
-
Magnesium sulphate in the management of patients with aneurysmal subar...
-
Risk Factors and Medical Management of Vasospasm After Subarachnoid He...
-
How Should Aneurysmal Subarachnoid Hemorrhage Be Managed?
-
A meta analysis of treating subarachnoid hemorrhage with magnesium sul...
-
Magnesium and aspirin treatment in patients with subarachnoid haemorrh...
-
Calcium Homeostasis During Magnesium Treatment in Aneurysmal Subarachn...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
World Stroke Organization members can access journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
